Three articles regarding the neuromechanism underlying analgesic effects of paroxetine and rizatriptan benzoate and the neurogenic nitric oxide in the central nociceptive transmission of migraine attacks were published in *Neural Regeneration Research*. We hope that our readers find these papers useful to their research.

**Abstract**

In this study, a model of migraine was established by electrical stimulation of the supe-rior sagittal sinus in rats. These rats were then treated orally with paroxetine at doses of 2.5, 5, or 10 mg/kg per day for 14 days. Following treatment, mechanical withdrawal thresholds were significantly higher, extracellular concentrations of 5-hydroxytryptamine in the periaqueductal grey matter and nucleus reticularis gigan-tocellularis were higher, and the expression of phosphorylated p38 in the trigeminal nucleus caudalis was lower. Our experimental findings suggest that paroxetine has analgesic effects in a rat migraine model, which are mediated by inhibition of p38 phosphorylation.

![Paroxetine engenders analgesic effects through inhibition of p38 phosphorylation in a rat migraine model\
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**Abstract**

The present study utilized a nitroglycerin-induced rat model of migraine to detect the effects of rizatriptan benzoate on proenkephalin and substance P gene expression in the midbrain using real-time quantitative polymerase chain reaction and investigated whether rizatriptan benzoate can regulate the endogenous pain modulatory system. The results showed that rizatriptan benzoate significantly reduced expression of the mRNAs for proenkephalin and substance P. Rizatriptan benzoate may inhibit the analgesic effect of the endogenous pain modulatory system.

![Rizatriptan benzoate influ-ences the endogenous pain modula-tory system in a rat model of migraine\
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**Abstract**

The present study used a cat model of migraine to represent migraine attacks in humans. We performed immunochemical staining of successive frozen sections of the brainstem and upper cervical spinal cord, and then used c-Fos protein expression to label nerve cell activation. We observed the effects of Nω-nitro-L-arginine methyl ester (L-NAME), a non-selective nitric oxide synthase inhibitor, and 7-nitroindozole (7-NI), a selective neuronal nitric oxide synthase inhibitor, on c-Fos and neuronal nitric oxide synthase expression, which were induced by electrical stimulation to the dura mater near the superior sagittal sinus. The results demonstrated that c-Fos or neuronal nitric oxide synthase immunoreactive cells were concentrated in the superficial layers (laminae I and II) of the spinal nucleus of trigeminal nerve. L-NAME and 7-NI pre-treatment significantly decreased c-Fos and neuronal nitric oxide synthase expression; and there was a significant linear correlation between c-Fos and neuronal nitric oxide synthase expression (*r* = 0.858 2, *P* \< 0.01). These findings suggest that neurogenic nitric oxide could facilitate migraine nociceptive transmission to second-order neurons of the trigeminal nerve. However, L-NAME and 7-NI may block the activation of neurons in the spinal nucleus of the trigeminal nerve by inhibiting nitric oxide synthesis, and thereby attenuate acute migraine attacks.
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